Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-11-06	US$11.61	+0.30%	170,677
26-11-05	US$11.58	-5.51%	97,139
26-11-04	US$12.25	+1.66%	80,616
26-11-03	US$12.05	-0.66%	91,643
26-11-02	US$12.13	+0.17%	100,129

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

11.61USD

Average target price

13.00USD

Spread / Average Target

+11.97%

Consensus

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amarin Corporation plc

Company calendar

Market Closed - Nasdaq 16:00:00 2026-11-06 EST			5-day change	1st Jan Change
11.61 ^USD	+0.30%		-4.13%	-16.80%

11-06	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
11-03	European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading	MT

Market Cap	245M 219M 201M 183M 345M 23B 356M 2.42B 964M 12.27B 918M 899M 38.74B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	76.2M 68.34M 62.46M 57.01M 107M 7.16B 111M 753M 300M 3.82B 286M 280M 12.07B	EV / Sales 2026 *	0.42x	EV / Sales 2027 *	0.31x
Free-Float	86.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	AMRN	Delayed
CBOE	AMRN	Real-time
Deutsche Boerse AG	EH3	Delayed
Tradegate	EH3	Real-time
Börse Stuttgart	EH3	Delayed
Boerse Muenchen	EH3	Real-time

11-06	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
11-03	European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading	MT
10-30	European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	MT
10-28	Amarin Corporation plc, Q3 2026 Earnings Call, Oct 28, 2026
10-28	Amarin Corporation plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026	CI
10-28	European Equities Traded in the US as American Depositary Receipts Steady in Wednesday Trading	MT
10-25	Amarin Corporation plc Provides Update on University of Leeds Sponsored Phase 3 Epa for Metastasis Trial 2 Evaluating Vazkepa/Vascepa Capsules in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases	CI
10-19	European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading	MT
10-12	European Equities Traded in the US as American Depositary Receipts Open Higher in Monday Trading	MT
09-25	European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week	MT
09-10	European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading	MT
09-08	Amarin, Kruengkao Form JV to Expand Entertainment Business	MT
09-01	European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading	MT

Amarin Corporation plc Stock

Stocks

AMRN

US0231114044

Biotechnology & Medical Research

Valuation: Amarin Corporation plc

Chart: Amarin Corporation plc

Latest news: Amarin Corporation plc

Last Transcript: Amarin Corporation plc

Analysts' recommendations: Amarin Corporation plc

Press Releases: Amarin Corporation plc

News in other languages: Amarin Corporation plc

Quotes and Performance

Price Extremes

Managers and Directors: Amarin Corporation plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

25-10-27	Amarin issues statement supporting FDA's action to revise labeling for fenofibrate drugs reinforcing a lack of cardiovascular benefit	RE
25-06-25	RBC Ups Recordati's Price Target on Cardiovascular Drug European Licensing Deal	MT
23-10-25	Jefferies Downgrades Amarin to Hold From Buy, Cuts Price Target to $1 From $3	MT
23-07-19	Northland Adjusts Price Target on Amarin to $1.25 From $2, Maintains Market Perform Rating	MT
23-01-06	Jefferies Upgrades Amarin to Buy From Hold, Adjusts Price Target to $3 From $1.30	MT

08-31	Amarin - New REDUCE-IT Legacy Analysis Presented at European Society of Cardiology Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients	AQ
08-31	Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026	AQ
08-28	New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients	AQ
08-24	New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026	AQ
07-29	Amarin: Q2 Earnings Snapshot	AQ

06-05	Afternoon Meeting: Los datos de empleo complican la labor de la Fed
06-05	Bourse : Lululemon dévisse, Blackstone se protège, Schneider émet 850 MEUR d'OCEANE
25-07-29	Recordati : firmato contratto di licenza e fornitura con Amarin per 25mln $ (RCO)
25-06-24	Recordati e Amarin commercializzano il farmaco cardiovascolare Vazkepa
22-03-29	Amarin reçoit un remboursement pour VAZKEPA® en Suède

1 day	+0.30%
1 week	-4.13%
Current month	-4.13%
1 month	-3.81%
3 months	-18.58%
6 months	-22.08%
Current year	-16.80%

1 week	11.39	12.57
1 month	11.25	13.18
Current year	11.25	17.31
1 year	11.25	17.31
3 years	7.08	27.4
5 years	7.08	91.8
10 years	7.08	522.4

Manager	Title	Age	Since
Aaron Berg CEO	Chief Executive Officer	63	2024-06-03
Peter Fishman DFI	Director of Finance/CFO	42	2024-10-22
Jonathan Provoost CMP	Compliance Officer	56	2023-11-14

Director	Title	Age	Since
Aaron Berg BRD	Director/Board Member	63	2024-06-03
Patrice Bonfiglio BRD	Director/Board Member	43	2023-02-27
Keith Horn BRD	Director/Board Member	67	2023-02-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/1/26	Peter Fishman	Exercice	Chief Financial Officer	781	0.0002%
7/1/26	David Keenan	Exercice	Chief Operating Officer	9,302	0.0022%
7/1/26	Steven Ketchum	Exercice	Chief Technology Officer	9,263	0.0022%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMARIN CORPORATION PLC	+0.30%	-4.13%	-25.91%	-25.12%	245M
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+53.62%	+61.75%	65.94B
LONZA GROUP AG	-1.34%	+2.98%	+24.79%	+100.18%	56.53B
ARGENX SE	+0.02%	+1.07%	+10.63%	+76.66%	56.88B
BEONE MEDICINES AG	+5.09%	+9.89%	+22.45%	+107.48%	46.49B
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+28.91%	+37.01%	44.8B
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+213.26%	+792.66%	41.59B
CELLTRION, INC.	-1.86%	+10.13%	+26.82%	+53.22%	35.35B
GENMAB A/S	-2.97%	-9.84%	+88.86%	+76.17%	33.29B
WUXI BIOLOGICS (CAYMAN) INC.	-2.18%	+7.06%	+36.06%	-4.95%	24.92B
Average	+0.31%	+2.51%	+47.95%	+127.51%	40.6B
Weighted average by Cap.	+0.21%	+3.40%	+53.07%	+142.86%

	2026 *	2027 *
Net sales	183M 164M 150M 137M 258M 17.24B 267M 1.81B 722M 9.2B 688M 673M 29.03B	189M 170M 155M 141M 267M 17.77B 275M 1.87B 745M 9.48B 710M 694M 29.93B
Net income	-23.57M -21.14M -19.32M -17.63M -33.22M -2.22B -34.27M -233M -92.85M -1.18B -88.46M -86.56M -3.73B	-13.16M -11.8M -10.79M -9.85M -18.55M -1.24B -19.13M -130M -51.84M -660M -49.39M -48.33M -2.08B
Net Debt	-168M -151M -138M -126M -237M -15.84B -245M -1.66B -664M -8.45B -632M -619M -26.68B	-187M -168M -153M -140M -264M -17.57B -272M -1.85B -736M -9.38B -702M -687M -29.6B